Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Vanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon

By Pharmaceutical Processing | March 8, 2011

Vanda Pharmaceuticals Inc., announced
today that the European Commission (EC) has granted orphan drug designation for
tasimelteon, an oral dual melatonin receptor agonist in Phase III clinical trails
for Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals with no light
perception. This follows the positive opinion on the designation that the
Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency
adopted previously in the November 2010 COMP Committee Meeting.

Orphan designation for a medicinal product by the EC
provides benefits that can take a variety of forms including tax incentives,
protocol assistance, eligibility for grants and initiatives supporting research
and development related to this orphan indication, reduction of marketing
application fees and annual fees for qualifying companies, and potential
marketing exclusivity for up to 10 years in the European Union.

“We are very pleased to receive orphan designation from
the European Commission,” said Mihael H. Polymeropoulos, M.D., President
and Chief Executive Officer of Vanda. “This status represents an acknowledgement
of the significant unmet medical need to develop and commercialize a treatment
that may alleviate sleep/wake problems in people who are totally blind with no
light perception.”  

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards